MIAMI, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”) today announced the appointment of Saphire Longmore M.B.B.S., DM, to the role of Chief Medical Officer of Caribbean Affairs. Sen Dr. Longmore’s extensive career includes being a Consultant Psychiatrist at the University Hospital of the West Indies, she works in private practice and is a reappointed Government Senator in the Upper House of Parliament. In her previous years Dr. Longmore also represented Jamaica as Miss Jamaica Universe 2000 being the first and only fully qualified doctor to win a beauty pageant. Sen Dr. Longmore is the current President of the Jamaica Psychiatric Association.
Senator Dr. Longmore received her M.B.B.S and Doctor of Medicine in Psychiatry, from the University Hospital of the West Indies and has been practising medicine for over 20 years and currently focuses on a holistic delivery of psychiatric care to her clients. During her esteemed career she has been a lecturer in Neuroanatomy, a Chief Resident in Psychiatry, and a Resident in Psychiatry at the University Hospital of the West Indies. She is also a member of the American Psychiatric Association, the Medical Council of Jamaica, the General Medical Council of the United Kingdom, the Medical Association of Jamaica. Dr. Longmore has been a Board Member of the Jamaica Social Investment Fund, an Executive Director of the Jamaica Network of Seropositives, and is the Co-founder of the Jamaica Hooking on Phonics (J-HoP) Project. She currently serves on the Hope Zoo Restoration Board.
Senator Dr. Longmore said, “I am enthusiastic to be joining Mycotopia Therapies at such a pivotal stage in its growth. The covid pandemic has impacted the mental health of Jamaicans, much as it has elsewhere, within the psychiatric profession we are seeing increased incidence of depression, anxiety, suicidal ideations, substance use and relapse of other chronic mental illnesses such as schizophrenia and bipolar disorder. My goal as it relates to mental health, not just in Jamaica, but at regional and global global levels, is to have an impact on dealing with the pandemic of mental health issues that we anticipate coming out of covid as well as mental illnesses which preexisted the covid 19 pandemic. I look forward to working with the team at Mycotopia Therapies, providing some guidance on the issues at hand and bringing helpful options to those who maybe in need.”
“We are fortunate at Mycotopia Therapies to be able to tap into the experience of an individual like Senator Dr. Saphire Longmore,” stated Ben Kaplan, CEO of Mycotopia Therapies. Mr. Kaplan continued, “As a licensed Psychiatrist, Dr. Longmore called on Jamaicans to work together to remove the stigma of mental illness in society. As a Senator, she reflects a responsible dispensation of mental healthcare delivery in an effective way. She will be a tremendous asset to Mycotopia Therapies.”
About Mycotopia Therapies
Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Company’s website at: https://www.mycotopiatherapies.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in 20/20 Global, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Contact for 20/20 Global and Ehave
Media Inquiries and Investor Relation:
Gabe Rodriguez
Email: Erelations@gmail.com
Phone: (623) 261-9046
